PROFILPELAJAR.COM

LEK-8804

LEK-8804
Clinical data
Other namesLEK8804; 9,10-Didehydro-N-(2-propynyl)-6-methylergoline-8β-carboxamide; N-(2-Propynyl)ergine; N-(2-Propynyl)lysergamide
Drug classSerotonin receptor modulator; Serotonin 5-HT1A receptor agonist; Serotonin 5-HT2A receptor antagonist
ATC code
  • None
Identifiers
  • (6aR,9R)-7-methyl-N-prop-2-ynyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC19H19N3O
Molar mass305.381 g·mol−1
3D model (JSmol)
  • CN1C[C@@H](C=C2[C@H]1CC3=CNC4=CC=CC2=C34)C(=O)NCC#C
  • InChI=1S/C19H19N3O/c1-3-7-20-19(23)13-8-15-14-5-4-6-16-18(14)12(10-21-16)9-17(15)22(2)11-13/h1,4-6,8,10,13,17,21H,7,9,11H2,2H3,(H,20,23)/t13-,17-/m1/s1
  • Key:WZTGESDWBWZMSE-CXAGYDPISA-N

LEK-8804, also known as N-(2-propynyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to the psychedelic drug LSD.[1][2][3][4] It is the derivative of ergine (lysergic acid amide; LSA) with an N-(2-propynyl) substitution on the carboxamide moiety.[1]

The drug shows affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 0.56–0.6 nM, 15–60 nM, and 10–80 nM, respectively).[1][3] It also shows weaker affinity for dopamine and adrenergic receptors.[1][3] Based on animal behavioral studies, it is thought that LEK-8804 may act as a potent serotonin 5-HT1A receptor full agonist and serotonin 5-HT2A receptor antagonist.[1] For instance, it fully substitutes for the serotonin 5-HT1A receptor agonist 8-OH-DPAT in rodent drug discrimination tests and produces other serotonin 5-HT1A receptor agonist-like behavioral effects.[1][3] The drug does not induce the head-twitch response, a behavioral proxy of serotonin 5-HT2A receptor activation and psychedelic effects, in rodents.[1] Instead, it dose-dependently inhibits 5-hydroxytryptophan (5-HTP)- and DOI-induced head twitches.[1][3] On the other hand, LEK-8804 failed to substantially block the discriminative stimulus effects of DOI in rodent drug discrimination tests.[3] These findings suggest that LEK-8804 may actually be acting merely as a serotonin 5-HT1A receptor agonist without significant serotonin 5-HT2A receptor antagonism.[3]

Close analogues of LEK-8804 include LEK-8842, LEK-8829, and LEK-8841, among others.[5][6][7][8][9][10][11]

LEK-8804 was first described in the scientific literature by 1994.[1] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.[1]

See also

References

  1. ^ a b c d e f g h i j Krisch I, Bole-Vunduk B (February 1994). "Behavioral studies on LEK-8804, a new ergoline derivative with potent 5-HT1A receptor agonist and 5-HT2 receptor antagonist activity". Pharmacology, Biochemistry, and Behavior. 47 (2): 301–305. doi:10.1016/0091-3057(94)90014-0. PMID 8146221.
  2. ^ Kleven MS, Koek W (February 1996). "Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon". The Journal of Pharmacology and Experimental Therapeutics. 276 (2): 388–397. doi:10.1016/S0022-3565(25)12286-6. PMID 8632301.
  3. ^ a b c d e f g Kleven MS, Assié MB, Koek W (August 1997). "Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT(2A/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats". The Journal of Pharmacology and Experimental Therapeutics. 282 (2): 747–759. doi:10.1016/S0022-3565(24)36843-0. PMID 9262338.
  4. ^ Kleven MS, Koek W (January 1998). "Discriminative stimulus effects of 8-hydroxy-2-(di-n-propylamino)tetralin in pigeons and rats: species similarities and differences". The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 238–249. doi:10.1016/S0022-3565(24)37196-4. PMID 9435184.
  5. ^ Krisch I, Budihna MV, Rucman R (1992). "Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and alpha-adrenoceptors in rabbit isolated aorta". Pharmacology. 45 (4): 195–208. doi:10.1159/000138998. PMID 1332086.
  6. ^ Krisch I, Bole-Vunduk B, Pepelnak M, Lavric B, Ocvirk A, Budihna MV, et al. (October 1994). "Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841". The Journal of Pharmacology and Experimental Therapeutics. 271 (1): 343–352. doi:10.1016/S0022-3565(25)22794-X. PMID 7965734.
  7. ^ Krisch I, Rucman R, Lavric A, Ocvirk M, Bole-Vunduk B (1996). "A New Ergoline Derivative, LEK-8829, as a Potential New Antipsychotic Drug". CNS Drug Reviews. 2 (3): 294–307. doi:10.1111/j.1527-3458.1996.tb00303.x. ISSN 1080-563X.
  8. ^ Zivin M, Sprah L, Sket D (November 1996). "The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions". British Journal of Pharmacology. 119 (6): 1187–1196. doi:10.1111/j.1476-5381.1996.tb16021.x. PMC 1915887. PMID 8937722.
  9. ^ Zivin M, Sprah L, Sket D (May 1998). "Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine". European Journal of Pharmacology. 349 (2–3): 151–157. doi:10.1016/s0014-2999(98)00287-8. PMID 9671092.
  10. ^ Glavan G, Sket D, Zivin M (February 2002). "Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats". Molecular Pharmacology. 61 (2): 360–368. doi:10.1124/mol.61.2.360. PMID 11809861.
  11. ^ Živin M (2010). "Potential applications of dopamine D1 agonist and D2 antagonist LEK-8829" (PDF). Slovenski Veterinarski Zbornik [Slovenian Veterinary Research]. 47 (4): 175–180.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.